SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALO', Girolamo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.297
AS - Asia 15.844
EU - Europa 8.579
SA - Sud America 2.322
AF - Africa 341
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 15
Totale 60.427
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.704
SG - Singapore 5.992
CN - Cina 3.899
DE - Germania 1.807
BR - Brasile 1.785
VN - Vietnam 1.776
UA - Ucraina 1.469
IT - Italia 1.437
HK - Hong Kong 1.215
GB - Regno Unito 961
TR - Turchia 956
FI - Finlandia 767
FR - Francia 534
BD - Bangladesh 523
RU - Federazione Russa 416
SE - Svezia 379
JP - Giappone 355
IN - India 309
CA - Canada 296
MX - Messico 213
PL - Polonia 213
AR - Argentina 192
ID - Indonesia 177
IQ - Iraq 122
NL - Olanda 122
ZA - Sudafrica 121
BE - Belgio 90
EC - Ecuador 88
PK - Pakistan 82
ES - Italia 73
CO - Colombia 63
LT - Lituania 57
MA - Marocco 57
SA - Arabia Saudita 53
IE - Irlanda 52
VE - Venezuela 51
PH - Filippine 46
UZ - Uzbekistan 46
MY - Malesia 45
CL - Cile 42
CZ - Repubblica Ceca 38
PY - Paraguay 37
TN - Tunisia 37
AT - Austria 36
AE - Emirati Arabi Uniti 32
NP - Nepal 28
EG - Egitto 26
KE - Kenya 25
JO - Giordania 23
UY - Uruguay 23
PE - Perù 21
AZ - Azerbaigian 20
IR - Iran 20
AU - Australia 18
DZ - Algeria 18
CH - Svizzera 17
AL - Albania 16
IL - Israele 16
KR - Corea 16
JM - Giamaica 15
BO - Bolivia 13
DO - Repubblica Dominicana 12
TH - Thailandia 12
LB - Libano 11
BG - Bulgaria 10
RO - Romania 10
SN - Senegal 10
ET - Etiopia 9
MD - Moldavia 9
NZ - Nuova Zelanda 9
PA - Panama 9
BH - Bahrain 8
GR - Grecia 8
HN - Honduras 8
DK - Danimarca 7
HR - Croazia 7
KZ - Kazakistan 7
NG - Nigeria 7
NI - Nicaragua 7
RS - Serbia 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
A2 - ???statistics.table.value.countryCode.A2??? 6
CY - Cipro 6
GY - Guiana 6
CR - Costa Rica 5
EU - Europa 5
LV - Lettonia 5
NO - Norvegia 5
OM - Oman 5
PS - Palestinian Territory 5
PT - Portogallo 5
AM - Armenia 4
KG - Kirghizistan 4
KH - Cambogia 4
LK - Sri Lanka 4
LU - Lussemburgo 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
Totale 60.348
Salva come PNG Salva come JPEG
Città #
Singapore 3.799
Ashburn 3.730
Fairfield 3.307
Woodbridge 2.892
Houston 1.997
San Jose 1.870
Jacksonville 1.598
Ann Arbor 1.518
Chandler 1.393
Seattle 1.359
Beijing 1.195
Santa Clara 1.193
Hong Kong 1.183
Wilmington 1.182
Cambridge 1.156
Dallas 1.128
Munich 617
Ho Chi Minh City 579
Izmir 548
New York 504
Los Angeles 488
Nanjing 457
Hanoi 370
Princeton 355
Tokyo 339
Ferrara 330
Helsinki 318
Lauterbourg 308
San Diego 290
Boardman 264
Milan 245
Shanghai 211
São Paulo 200
Warsaw 191
London 142
Council Bluffs 139
Nanchang 139
Shenyang 129
Dearborn 128
Turku 128
Mexico City 119
Orem 117
Falkenstein 109
Tianjin 104
Hefei 103
Frankfurt am Main 100
Jakarta 99
Buffalo 98
Da Nang 94
The Dalles 93
Falls Church 92
Brooklyn 91
Montreal 85
Brussels 84
Chicago 83
Atlanta 82
Hebei 81
San Mateo 81
Moscow 79
Norwalk 78
Toronto 77
Jiaxing 75
Bremen 74
Johannesburg 74
Denver 73
Changsha 70
Chennai 67
Mountain View 64
Redwood City 64
Rio de Janeiro 64
Haiphong 62
San Francisco 60
Jinan 59
Bologna 56
Phoenix 56
Stockholm 55
Guangzhou 53
Washington 51
Dublin 50
Addison 48
Auburn Hills 48
Manchester 48
Boston 47
Dhaka 46
Philadelphia 46
Amsterdam 45
Dong Ket 45
Baghdad 44
Kunming 44
Zhengzhou 44
Mumbai 43
Poplar 42
Tashkent 42
Belo Horizonte 37
Ankara 36
Rome 36
Hải Dương 34
Lahore 33
Columbus 32
Biên Hòa 30
Totale 41.865
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands 995
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 394
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 376
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 337
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 331
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 317
In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl 295
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 293
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 290
A new selective antagonist of the nociceptin receptor 273
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 272
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 269
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 269
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 266
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 263
Effects of vasoactive agents in healthy and diseased human saphenous veins 263
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor 261
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 261
A new ligand for the urotensin II receptor 254
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 253
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 251
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 247
The effect of guanethidine and local anaesthetics on the electrically stimulated mouse vas deferens 245
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 243
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 243
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 242
Actual concept of "probiotics": is it more functional to science or business? 240
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 240
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 239
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 239
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 237
A simple method for electrical field stimulation of cultured granule cells 236
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 235
[Nphe(1)]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices 235
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 235
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 234
Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies 233
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 233
Cardiovascular effects of nociceptin in unanesthetized mice 231
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 231
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 230
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 230
Structural Bacterial Molecules as Potential Candidates for an Evolution of the Classical Concept of Probiotics 229
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 229
Characterisation of the novel mixed Mu-NOP peptide ligand dermorphin-N/OFQ (DeNo) 228
Modulation of the NOP receptor signaling affects resilience to acute stress 228
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120 226
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials 225
[Nphe(1),Arg(14),Lys(15)]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray 224
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 224
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 223
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 222
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 221
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 220
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 219
Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation 219
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 217
Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone 217
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 216
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 216
[Nphe(1)]-Nociceptin (1-13)-NH2, a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats 215
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 215
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 215
Pharmacological characterization of tachykinin tetrabranched derivatives 215
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems 214
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 214
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 213
Emergency admissions of opioid drug-abusers for overdose. A chronobiological study of enhanced risk 212
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 212
B1 and B2 kinin receptors in various species 212
Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration 212
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 212
Pharmacological characterisation of novel kinin B2 receptor ligands 211
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 210
In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 210
Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity 208
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction 208
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 208
Neuropeptide S receptor ligands: a patent review (2005-2016) 207
Sudden death from pulmonary thromboembolism: chronobiological aspects 206
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 206
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 206
null 205
Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2 205
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 205
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 204
Pharmacological characterization of nociceptin receptor: an in vitro study 204
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands 203
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 203
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 202
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 201
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 201
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 201
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 201
Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505). 200
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 200
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 199
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 199
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 198
(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 197
Totale 24.033
Salva come PNG Salva come JPEG
Categoria #
all - tutte 269.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.786
Totale 274.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021278 0 0 0 0 0 0 0 0 0 0 0 278
2021/20223.644 144 369 312 217 203 190 217 236 156 302 313 985
2022/20233.455 379 160 114 414 572 485 177 315 470 21 196 152
2023/20241.783 196 229 88 50 99 310 74 142 35 30 53 477
2024/20257.710 184 203 632 256 875 769 271 496 1.226 795 1.075 928
2025/202622.497 2.223 1.107 2.409 2.779 3.039 1.412 2.592 1.114 1.963 2.327 1.002 530
Totale 60.928